[go: up one dir, main page]

PE20110684A1 - Agonistas de los receptores de la melanocortina - Google Patents

Agonistas de los receptores de la melanocortina

Info

Publication number
PE20110684A1
PE20110684A1 PE2011000970A PE2011000970A PE20110684A1 PE 20110684 A1 PE20110684 A1 PE 20110684A1 PE 2011000970 A PE2011000970 A PE 2011000970A PE 2011000970 A PE2011000970 A PE 2011000970A PE 20110684 A1 PE20110684 A1 PE 20110684A1
Authority
PE
Peru
Prior art keywords
pyrrolidin
carbonyl
cycloalkyl
tert
halogen
Prior art date
Application number
PE2011000970A
Other languages
English (en)
Inventor
Koo Lee
Sang Dae Lee
Sang Pil Moon
In Ae Ahn
Sung Pil Choi
Hyun Ho Lee
Dong Sup Shim
Soo Yong Chung
Hyun Min Lee
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of PE20110684A1 publication Critical patent/PE20110684A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIRROLIDINA DE FORMULA (1) DONDE R1 ES H, ALQUILO(C1-C10), CICLOALQUILO(C3-C7), ARILO(C6-C10), ENTRE OTROS; R2 ES FENILO O HETEROARILO DE SEIS MIEMBROS OPCIONALMENTE SUSTITUIDO CON HALOGENO, HIDROXI, CN, ENTRE OTROS; R3 ES H, ALQUILO(C1-C6) O CICLOALQUILO(C3-C7) OPCIONALMENTE SUSTITUIDO CON HALOGENO, METILO, AMINO, ENTRE OTROS; R4 ES CICLOALQUILO(C4-C7), FENILO, HETEROARILO DE SEIS MIEMBROS, ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS CON HALOGENO, HIDROXI, ENTRE OTROS; R5 ES ALQUILO(C1-C6), DIFLUOROMETILO, CICLOALQUILO(C3-C8), AMINO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-{(3S,5S)-1-{[(3S,4R)-1-TERT-BUTIL-4-(4-CLOROFENIL)-PIRROLIDIN-3-IL]CARBONIL}-5-[(4-METILPIPERAZIN-1-IL)CARBONIL]PIRROLIDIN-3-IL}-N-(4,4-DIMETILCICLOHEXIL)-ACETAMIDA; N-[(3S,5S)-1-{[(3S,4R)-1-TERT-BUTIL-4-(2,4-DIFLUOROFENIL)PIRROLIDIN-3-IL]CARBONIL}-5-(PIPERAZIN-1-ILCARBONIL)-PIRROLIDIN-3-IL]-N-(4,4-DIMETILCICLOHEXIL)ACETAMIDA; (2S)-N-{(3S,5S)-1-{[(3S,4R)-1-TERT-BUTIL-4-(4-CLOROFENIL)PIRROLIDIN-3-IL]CARBONIL}-5-[(4-METILPIPERAZIN-1-IL)CARBONIL]PIRROLIDIN-3-IL}-N-(4,4-DIMETILCICLOHEXIL)-TETRAHIDROFURAN-2-CARBOXAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR DE LA MELANOCORTINA SIENDO UTILES EN EL TRATAMIENTO DE LA OBESIDAD, DIABETES, INFLAMACION
PE2011000970A 2008-11-12 2009-11-10 Agonistas de los receptores de la melanocortina PE20110684A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20080112403 2008-11-12

Publications (1)

Publication Number Publication Date
PE20110684A1 true PE20110684A1 (es) 2011-09-28

Family

ID=42165801

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000970A PE20110684A1 (es) 2008-11-12 2009-11-10 Agonistas de los receptores de la melanocortina

Country Status (26)

Country Link
US (4) US8039622B2 (es)
EP (1) EP2350060B1 (es)
JP (1) JP5399506B2 (es)
KR (1) KR101141976B1 (es)
CN (1) CN102282141B (es)
AR (1) AR074109A1 (es)
AU (1) AU2009314827B2 (es)
BR (1) BRPI0921063B8 (es)
CA (1) CA2742248C (es)
CL (1) CL2011001073A1 (es)
CO (1) CO6362006A2 (es)
CR (1) CR20110250A (es)
EA (1) EA019146B1 (es)
EC (1) ECSP11011026A (es)
GE (1) GEP20135850B (es)
IL (1) IL212468A0 (es)
MA (1) MA32774B1 (es)
MX (1) MX2011004583A (es)
NZ (1) NZ592512A (es)
PE (1) PE20110684A1 (es)
TN (1) TN2011000222A1 (es)
TW (1) TWI389903B (es)
UA (1) UA99555C2 (es)
UY (1) UY32238A (es)
WO (1) WO2010056022A2 (es)
ZA (1) ZA201103154B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99555C2 (en) * 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
CA2825098C (en) 2011-01-27 2020-03-10 Universite De Montreal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
EP3988108A1 (en) 2011-12-29 2022-04-27 Rhythm Pharmaceuticals, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
JP6235560B2 (ja) 2012-04-25 2017-11-22 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ （３，４−ジクロロ−フェニル）−（（ｓ）−３−プロピル−ピロリジン−３−イル）−メタノン塩酸塩及び製造方法
CN103420981A (zh) * 2012-05-21 2013-12-04 中国医学科学院药物研究所 含有取代吡咯烷基的硫代吗啉类化合物
JP6940853B2 (ja) 2015-09-30 2021-09-29 リズム ファーマシューティカルズ， インコーポレイテッド メラノコルチン４受容体経路関連障害を治療する方法
US20210169969A1 (en) 2018-04-06 2021-06-10 Leonardus H.T. Van Der Ploeg Compositions for treating kidney disease
JP7467510B2 (ja) 2019-11-07 2024-04-15 エルジー・ケム・リミテッド メラノコルチン－４受容体アゴニスト
IL302427A (en) * 2020-10-29 2023-06-01 Lg Chemical Ltd A crystalline structure of a melanocortin receptor agonist and a method for its preparation
JP2023548161A (ja) * 2020-10-29 2023-11-15 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物の結晶形ｉｖおよびその製造方法
KR102672625B1 (ko) 2020-10-29 2024-06-07 주식회사 엘지화학 멜라노코르틴 수용체 작용제 화합물의 결정형 ⅱ 및 이의 제조방법
CA3195214A1 (en) * 2020-10-29 2022-05-05 Jin Ok HAM Amorphous melanocortin-4 receptor agonist
CA3195304A1 (en) 2020-10-29 2022-05-05 Jin Ok HAM Crystalline form iii of melanocortin receptor agonist compound and preparation method therefor
JP7662796B2 (ja) * 2020-12-22 2025-04-15 エルジー・ケム・リミテッド 無定形のメラノコルチン受容体アゴニストおよびその製造方法
WO2022139443A1 (ko) * 2020-12-22 2022-06-30 주식회사 엘지화학 멜라노코르틴 수용체 작용제 화합물의 결정형 i 및 이의 제조방법
EP4249485A4 (en) 2020-12-22 2024-05-15 Lg Chem, Ltd. CRYSTALLINE FORM III OF A MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD OF PREPARING THE SAME
CN116648249A (zh) 2020-12-22 2023-08-25 株式会社Lg化学 黑皮质素受体激动剂化合物的结晶形式ii及其制备方法
CA3202315A1 (en) * 2020-12-22 2022-06-30 Hee Dong Park Use as selective agonist of malanocortin-4 receptor
AU2022209657B2 (en) * 2021-01-21 2025-06-05 Lg Chem, Ltd. Uses of melanocortin-4 receptor agonist
US20240190856A1 (en) * 2021-02-26 2024-06-13 Lg Chem, Ltd. Melanocortin-4 receptor agonist
BR112023022863A2 (pt) * 2021-05-06 2024-01-23 Lg Chemical Ltd Forma cristalina vii do composto agonista do receptor de melanocortina e método para preparar o mesmo
CN117242064A (zh) * 2021-05-06 2023-12-15 株式会社Lg 化学 黑皮质素受体激动剂化合物的晶型v及其制备方法
CN117255788A (zh) * 2021-05-07 2023-12-19 株式会社Lg化学 黑皮质素受体激动剂化合物的有机酸盐的晶型iv及其制备方法
WO2022235103A1 (ko) * 2021-05-07 2022-11-10 주식회사 엘지화학 멜라노코르틴 수용체 작용제 화합물의 황산염의 결정형 및 이의 제조방법
US20240239769A1 (en) 2021-05-07 2024-07-18 Lg Chem, Ltd. Co-crystal of melanocortin receptor agonist compound and vanillin and method for preparing same

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534503B1 (en) * 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
EP1187614A4 (en) 1999-06-04 2005-06-22 Merck & Co Inc SUBSTITUTED PIPERIDINES THAN MELANOCORTIN-4 RECEPTOR AGONISTS
GB0002059D0 (en) 2000-01-28 2000-03-22 Melacure Therapeutics Ab Novel aromatic amines
EP1268000A4 (en) 2000-03-23 2004-12-29 Merck & Co Inc SPIROPIPERID DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS
EP1268449A4 (en) 2000-03-23 2004-09-15 Merck & Co Inc SUBSTITUTED PIPERIDINE AS MELANOCORTIN RECEPTOR AGONISTS
GB0019359D0 (en) * 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
CA2419310A1 (en) 2000-08-23 2002-02-28 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
DZ3415A1 (fr) 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
JP2004523530A (ja) 2001-01-23 2004-08-05 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニストとしてのピペラジンおよびピペリジン誘導体
US7169777B2 (en) 2001-01-23 2007-01-30 Eli Lilly And Company Melanocortin receptor agonists
EP1368339A1 (en) 2001-01-23 2003-12-10 Eli Lilly & Company Substituted piperidines/piperazines as melanocortin receptor agonists
AU2002255597B8 (en) 2001-02-28 2006-10-26 Merck Sharp & Dohme Corp. Acylated piperidine derivatives as melanocortin-4 receptor agonists
US7012084B2 (en) 2001-02-28 2006-03-14 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2002068388A2 (en) 2001-02-28 2002-09-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
DE60216747T2 (de) 2001-04-09 2007-10-04 Novartis Vaccines and Diagnostics, Inc., Emeryville Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
AR043434A1 (es) 2003-03-03 2005-07-27 Merck & Co Inc Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos
ATE474577T1 (de) 2003-03-26 2010-08-15 Merck Sharp & Dohme Bicyclische piperidin-derivate als melanocortin-4 rezeptor-agonisten
WO2005040109A1 (en) 2003-10-22 2005-05-06 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
TWI341835B (en) * 2003-11-12 2011-05-11 Lg Life Sciences Ltd Melanocortin receptor agonists
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
CN1984662A (zh) 2004-07-16 2007-06-20 默克公司 用作黑皮质素－4受体激动剂的酰基化哌啶衍生物
JP2008506779A (ja) 2004-07-19 2008-03-06 メルク　エンド　カムパニー　インコーポレーテッド メラノコルチン−４受容体作用薬としてのアシル化ピペリジン誘導体
DE102005000666B3 (de) 2005-01-04 2006-10-05 Sanofi-Aventis Deutschland Gmbh Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2007015157A2 (en) 2005-08-01 2007-02-08 Pfizer Limited Mc4r-ag0nists for the treatment of urinary tract dysfunction
US20080269233A1 (en) 2005-08-04 2008-10-30 Mark David Andrews Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JP2009510069A (ja) 2005-09-30 2009-03-12 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体作働薬としてのアシル化ピペリジン誘導体
JP2009511631A (ja) 2005-10-18 2009-03-19 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
JP2007131570A (ja) 2005-11-09 2007-05-31 Mitsubishi Pharma Corp 新規なアミノピロリジン誘導体
WO2007096186A1 (en) 2006-02-23 2007-08-30 Santhera Pharmaceuticals (Schweiz) Ag Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators
SG185849A1 (en) 2006-02-23 2012-12-28 Pfizer Ltd Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
HUE029016T2 (en) 2006-06-09 2017-02-28 Synact Pharma Aps Phenylpyrrolidinoguanidine derivatives
TWI332501B (en) * 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
US20090253744A1 (en) 2006-09-27 2009-10-08 Bakshi Raman K Acylated piperidine derivatives as melanocortin-4 receptor modulators
UA99555C2 (en) * 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists

Also Published As

Publication number Publication date
JP5399506B2 (ja) 2014-01-29
TN2011000222A1 (en) 2012-12-17
US20110237795A1 (en) 2011-09-29
ECSP11011026A (es) 2011-06-30
UA99555C2 (en) 2012-08-27
EA019146B1 (ru) 2014-01-30
BRPI0921063B1 (pt) 2021-03-16
CA2742248C (en) 2014-01-14
MX2011004583A (es) 2011-06-01
IL212468A0 (en) 2011-06-30
EA201170676A1 (ru) 2011-12-30
US8039622B2 (en) 2011-10-18
CR20110250A (es) 2011-08-26
US8183243B2 (en) 2012-05-22
KR101141976B1 (ko) 2012-05-07
AU2009314827A1 (en) 2010-05-20
CN102282141A (zh) 2011-12-14
CN102282141B (zh) 2014-09-10
US20100120783A1 (en) 2010-05-13
TW201022246A (en) 2010-06-16
KR20100053458A (ko) 2010-05-20
CO6362006A2 (es) 2012-01-20
AU2009314827B2 (en) 2012-04-05
CA2742248A1 (en) 2010-05-20
MA32774B1 (fr) 2011-11-01
EP2350060A4 (en) 2012-07-25
US20110224219A1 (en) 2011-09-15
WO2010056022A2 (en) 2010-05-20
AR074109A1 (es) 2010-12-22
US8288386B2 (en) 2012-10-16
ZA201103154B (en) 2012-01-25
UY32238A (es) 2010-01-05
BRPI0921063A2 (pt) 2015-08-25
US8236955B2 (en) 2012-08-07
BRPI0921063B8 (pt) 2021-05-25
TWI389903B (zh) 2013-03-21
EP2350060A2 (en) 2011-08-03
GEP20135850B (en) 2013-06-10
JP2012508730A (ja) 2012-04-12
NZ592512A (en) 2012-12-21
EP2350060B1 (en) 2013-09-18
WO2010056022A3 (en) 2010-09-10
US20110245500A1 (en) 2011-10-06
CL2011001073A1 (es) 2011-10-07

Similar Documents

Publication Publication Date Title
PE20110684A1 (es) Agonistas de los receptores de la melanocortina
PE20091974A1 (es) Derivados de indazoles sustituidos con fenil o piridinilo
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
PE20121058A1 (es) Compuestos que modulan el receptor de androgenos
PE20081659A1 (es) Agonistas de gpcr
PE20071152A1 (es) Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
PE20110237A1 (es) Derivados de ciclohexilamida como antagonistas del receptor del factor de liberacion de corticotropina (crf-1)
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
RU2015119640A (ru) Соединения n-замещенного индазол-сульфонамида с избирательной активностью в потенциал-зависимых натриевых каналах
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20141375A1 (es) Activadores de glucoquinasa
PE20141228A1 (es) Derivados de pirrolopirimidina y purina
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
PE20061366A1 (es) Compuestos y composiciones como inhibidores de quinasa de proteina
PE20080409A1 (es) Compuestos que modulan en el receptor cb2
PE20090240A1 (es) Derivados heterociclicos sustituidos y su uso farmaceutico y composiciones
PE20121314A1 (es) Derivados de 4-aminociclohexano sustituido
PE20110341A1 (es) COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
PE20061377A1 (es) Compuestos heterociclicos fusionados
PE20090620A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
PE20090592A1 (es) Nuevos derivados de piperazina-amida
PE20091425A1 (es) Derivados de aminotiazol

Legal Events

Date Code Title Description
FC Refusal